STOCK TITAN
  1. Home
  2. Sec-filings
  3. GPCR
  4. [Form 4] Structure Therapeutics Inc. Insider Trading Activity

Structure Therapeutics (GPCR) awards options and RSUs to its CCO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Structure Therapeutics Chief Commercial Officer John Joseph Berrios received equity awards on 2026-08-06. He was granted 174,612 share options with an exercise price of 17.54 per Ordinary Share, expiring 2036-08-05, plus 140,766 restricted share units. The RSUs vest one-fourth annually from August 6, 2026, and the options vest one-fourth on that date and in thirty-six equal monthly installments thereafter, in each case subject to his continued service. Each Ordinary Share may be represented by an ADS, with each ADS representing three Ordinary Shares.

Positive

  • None.

Negative

  • None.
Insider Berrios John Joseph
Role Chief Commercial Officer
Type Security Shares Price Value
Grant/Award Share option (right to buy) F3, F4, F1 174,612 $0.00 $0.00
Grant/Award Ordinary Shares F1, F2 140,766 $0.00 $0.00
Holdings After Transaction: Share option (right to buy) — 174,612 shares (Direct); Ordinary Shares — 140,766 shares (Direct)
Footnotes (4)
  1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
  2. F2. Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates.
  3. F3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
  4. F4. One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
Options granted 174,612 shares Share options granted to Chief Commercial Officer on 2026-08-06
Option exercise price 17.54 per share Exercise price for share options granted on 2026-08-06
Option expiration 2036-08-05 Expiration date of the granted share options
RSUs granted 140,766 units Restricted share units representing Ordinary Shares granted on 2026-08-06
ADS to Ordinary Share ratio 1 ADS : 3 Ordinary Shares Each ADS represents three Ordinary Shares of Structure Therapeutics
Options underlying shares 174,612 Ordinary Shares Ordinary Shares underlying the granted share options
RSU vesting reference date August 6, 2026 RSUs vest one-fourth annually on each anniversary of this date
restricted share units ("RSUs") financial
"Represents the grant of restricted share units ("RSUs"), each of which represents"
American Depositary Shares ("ADSs") financial
"may be represented by American Depositary Shares ("ADSs"). Each ADS represents"
American Depositary Shares (ADSs) are U.S.-listed certificates issued by a bank that represent ownership of a specified number of a foreign company’s ordinary shares, letting U.S. investors buy and sell those interests in U.S. dollars on American markets. They matter because they make investing in overseas companies as easy as buying a domestic stock—streamlining currency, settlement, and recordkeeping—while still exposing investors to foreign-market risks like exchange rates and local regulations.
fair market value financial
"The option exercise price per share is equal to the fair market value per"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
vesting financial
"One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What equity awards did GPCR grant to Chief Commercial Officer John Joseph Berrios?
John Joseph Berrios received two equity awards: 174,612 share options and 140,766 restricted share units, each linked to Ordinary Shares of Structure Therapeutics. The options carry an exercise price of 17.54 per share and expire on August 5, 2036.

How do the RSUs granted by GPCR to its Chief Commercial Officer vest?
The 140,766 RSUs vest in four annual installments. One-fourth of the restricted share units vests on each anniversary of August 6, 2026, provided John Joseph Berrios continues in service on each vesting date.

What are the terms of the share options granted by GPCR to its CCO?
The grant includes 174,612 share options with an exercise price of 17.54 per Ordinary Share and an expiration date of August 5, 2036. One-fourth vests on August 6, 2027, with the remaining shares vesting in thirty-six equal monthly installments thereafter.

Were the GPCR equity awards to John Joseph Berrios made under a Rule 10b5-1 plan?
The awards were not reported as made under a Rule 10b5-1 plan. The Rule 10b5-1 checkbox was not selected, indicating no affirmed pre-arranged trading plan for these specific equity grants.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Berrios John Joseph
(Last)(First)(Middle)
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)08/06/2026A(2)140,766A$0140,766D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy)$17.54(3)08/06/2026A174,612 (4)08/05/2036Ordinary Shares(1)174,612$0174,612D
Explanation of Responses:
1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. Represents the grant of restricted share units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of August 6, 2026, subject to Reporting Person's continued service on such dates.
3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
4. One-fourth of the shares vest on the first anniversary of August 6, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
/s/ Jun Yoon, Attorney-in-Fact08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR